Novo Holdings A/S has announced its plan to acquire a controlling stake of approximately 60% in Single Use Support, a company specializing in life science tools and technologies for pharmaceutical production. The acquisition includes participation from the two company founders, who will each retain 10%, and Danaher, which will maintain a 20% share. Founded in 2017 in Kufstein, Austria by Johannes Kirchmair and Thomas Wurm, Single Use Support has become a key player in bioprocessing. They offer solutions for biological drug substances and advanced therapies that are already being used by leading pharmaceutical companies. This transaction, slated to be complete pending regulatory approvals, highlights Novo Holdings’ expansion into the DACH region and underscores its commitment to advancing healthcare therapies. Legal advisories for the deal include Kromann Reumert, DORDA, Linklaters, and Wilson Sonsini, while William Blair and Jefferies LLC served as financial advisors.

Life Sciences, Pharmaceuticals, Private Equity,Denmark, Austria, Europe

https://contentapi.cision.com/api/v1.0/releases/20240515EN13996